Literature DB >> 23329594

Timely and complete publication of economic evaluations alongside randomized controlled trials.

Joanna C Thorn1, Sian M Noble, William Hollingworth.   

Abstract

BACKGROUND AND AIMS: Little is known about the extent and nature of publication bias in economic evaluations. Our objective was to determine whether economic evaluations are subject to publication bias by considering whether economic data are as likely to be reported, and reported as promptly, as effectiveness data.
METHODS: Trials that intended to conduct an economic analysis and ended before 2008 were identified in the International Standard Randomised Controlled Trial Number (ISRCTN) register; a random sample of 100 trials was retrieved. Fifty comparator trials were randomly drawn from those not identified as intending to conduct an economic study. The trial start and end dates, estimated sample size and funder type were extracted. For trials planning economic evaluations, effectiveness and economic publications were sought; publication dates and journal impact factors were extracted. Effectiveness abstracts were assessed for whether they reached a firm conclusion that one intervention was most effective. Primary investigators were contacted about reasons for non-publication of results, or reasons for differential publication strategies for effectiveness and economic results.
RESULTS: Trials planning an economic study were more likely to be funded by government (p = 0.01) and larger (p = 0.003) than other trials. The trials planning an economic evaluation had a mean of 6.5 (range 2.7-13.2) years since the trial end in which to publish their results. Effectiveness results were reported by 70 %, while only 43 % published economic evaluations (p < 0.001). Reasons for non-publication of economic results included the intervention being ineffective, and staffing issues. Funding source, time since trial end and length of study were not associated with a higher probability of publishing the economic evaluation. However, studies that were small or of unknown size were significantly less likely to publish economic evaluations than large studies (p < 0.001). The authors' confidence in labelling one intervention clearly most effective did not affect the probability of publication. The mean time to publication was 0.7 years longer for cost-effectiveness data than for effectiveness data where both were published (p = 0.001). The median journal impact factor was 1.6 points higher for effectiveness publications than for the corresponding economic publications (p = 0.01). Reasons for publishing in different journals included editorial decision making and the additional time that economic evaluation takes to conduct.
CONCLUSIONS: Trials that intend to conduct an economic analysis are less likely to report economic data than effectiveness data. Where economic results do appear, they are published later, and in journals with lower impact factors. These results suggest that economic output may be more susceptible than effectiveness data to publication bias. Funders, grant reviewers and trialists themselves should ensure economic evaluations are prioritized and adequately staffed to avoid potential problems with bias.

Mesh:

Year:  2013        PMID: 23329594     DOI: 10.1007/s40273-012-0004-7

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  15 in total

Review 1.  Publication and related biases.

Authors:  F Song; A J Eastwood; S Gilbody; L Duley; A J Sutton
Journal:  Health Technol Assess       Date:  2000       Impact factor: 4.014

Review 2.  Delays in publication of cost utility analyses conducted alongside clinical trials: registry analysis.

Authors:  Dan Greenberg; Allison B Rosen; Natalia V Olchanski; Patricia W Stone; John Nadai; Peter J Neumann
Journal:  BMJ       Date:  2004-04-20

Review 3.  Modeling in pharmacoeconomic studies: funding sources and outcomes.

Authors:  Livio Garattini; Daniela Koleva; Gianluigi Casadei
Journal:  Int J Technol Assess Health Care       Date:  2010-07       Impact factor: 2.188

4.  Industry sponsored bias in cost effectiveness analyses.

Authors:  Ava John-Baptiste; Chaim Bell
Journal:  BMJ       Date:  2010-10-13

5.  The lag between effectiveness and cost-effectiveness evidence of new drugs. Implications for decision-making in health care.

Authors:  Boyka Stoykova; Michael Drummond; Marco Barbieri; Jos Kleijnen
Journal:  Eur J Health Econ       Date:  2003-11

6.  Negative results and impact factor: a lesson from neonatology.

Authors:  Yoav Littner; Francis B Mimouni; Shaul Dollberg; Dror Mandel
Journal:  Arch Pediatr Adolesc Med       Date:  2005-11

7.  Randomized trials with concurrent economic evaluations reported unrepresentatively large clinical effect sizes.

Authors:  Simon Gilbody; Peter Bower; Alex J Sutton
Journal:  J Clin Epidemiol       Date:  2007-03-26       Impact factor: 6.437

8.  Legislation for trial registration and data transparency.

Authors:  Zhao-Xiang Bian; Tai-Xiang Wu
Journal:  Trials       Date:  2010-05-26       Impact factor: 2.279

9.  Trial publication after registration in ClinicalTrials.Gov: a cross-sectional analysis.

Authors:  Joseph S Ross; Gregory K Mulvey; Elizabeth M Hines; Steven E Nissen; Harlan M Krumholz
Journal:  PLoS Med       Date:  2009-09-08       Impact factor: 11.069

Review 10.  Systematic review of the empirical evidence of study publication bias and outcome reporting bias.

Authors:  Kerry Dwan; Douglas G Altman; Juan A Arnaiz; Jill Bloom; An-Wen Chan; Eugenia Cronin; Evelyne Decullier; Philippa J Easterbrook; Erik Von Elm; Carrol Gamble; Davina Ghersi; John P A Ioannidis; John Simes; Paula R Williamson
Journal:  PLoS One       Date:  2008-08-28       Impact factor: 3.240

View more
  8 in total

1.  Economic Evaluations of Child Nutrition Interventions in Low- and Middle-Income Countries: Systematic Review and Quality Appraisal.

Authors:  Yeji Baek; Zanfina Ademi; Susan Paudel; Jane Fisher; Thach Tran; Lorena Romero; Alice Owen
Journal:  Adv Nutr       Date:  2022-02-01       Impact factor: 11.567

2.  Cost-Effectiveness Evaluations of Psychological Therapies for Schizophrenia and Bipolar Disorder: A Systematic Review.

Authors:  Gemma Elizabeth Shields; Deborah Buck; Jamie Elvidge; Karen Petra Hayhurst; Linda Mary Davies
Journal:  Int J Technol Assess Health Care       Date:  2019-07-22       Impact factor: 2.188

3.  Extent of non-publication in cohorts of studies approved by research ethics committees or included in trial registries.

Authors:  Christine Schmucker; Lisa K Schell; Susan Portalupi; Patrick Oeller; Laura Cabrera; Dirk Bassler; Guido Schwarzer; Roberta W Scherer; Gerd Antes; Erik von Elm; Joerg J Meerpohl
Journal:  PLoS One       Date:  2014-12-23       Impact factor: 3.240

4.  Impact of stakeholder perspectives on cost-effectiveness estimates of four specialized nutritious foods for preventing stunting and wasting in children 6-23 months in Burkina Faso.

Authors:  Ye Shen; Ilana R Cliffer; Devika J Suri; Breanne K Langlois; Stephen A Vosti; Patrick Webb; Beatrice L Rogers
Journal:  Nutr J       Date:  2020-02-27       Impact factor: 3.271

5.  Cost-effectiveness of Interventions for Chronic Fatigue Syndrome or Myalgic Encephalomyelitis: A Systematic Review of Economic Evaluations.

Authors:  M Cochrane; E Mitchell; W Hollingworth; E Crawley; D Trépel
Journal:  Appl Health Econ Health Policy       Date:  2021-03-01       Impact factor: 3.686

Review 6.  A review of economic evaluations of health care for people at risk of psychosis and for first-episode psychosis.

Authors:  Gemma E Shields; Deborah Buck; Filippo Varese; Alison R Yung; Andrew Thompson; Nusrat Husain; Matthew R Broome; Rachel Upthegrove; Rory Byrne; Linda M Davies
Journal:  BMC Psychiatry       Date:  2022-02-17       Impact factor: 3.630

7.  Preliminary investigation of economics issues in hospitalized patients with stroke.

Authors:  Zahra Tolou-Ghamari; Vahid Shaygannejad; Fariborz Khorvash
Journal:  Int J Prev Med       Date:  2013-05

Review 8.  Cost-effectiveness of strategies to improve the utilization and provision of maternal and newborn health care in low-income and lower-middle-income countries: a systematic review.

Authors:  Lindsay Mangham-Jefferies; Catherine Pitt; Simon Cousens; Anne Mills; Joanna Schellenberg
Journal:  BMC Pregnancy Childbirth       Date:  2014-07-22       Impact factor: 3.007

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.